Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA) ¹. The company's mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies for previously intractable oncogene amplified cancers ². ecDNA are large circular units of nuclear DNA found only in cancer cells, serving as a primary mechanism of gene amplification ³. Patients with oncogene amplified cancers generally show limited benefit from existing therapies and have worse survival rates ⁴. The company's approach, termed synthetic lethality, aims to inhibit targets essential for ecDNA functionality, preferentially killing ecDNA-enabled cancer cells while sparing healthy cells ⁵.

The company's core business model revolves around its proprietary Spyglass platform, which identifies targets crucial for ecDNA functionality in oncogene amplified cancer cells ⁶. Subsequently, Boundless Bio designs and develops small molecule drugs, or ecDNA-directed therapeutic candidates (ecDTx), to inhibit these identified targets ⁷. The company generates revenue through the potential commercialization of these ecDTx, although it has not generated any product sales revenue to date ⁸. Primary customer segments are patients with oncogene amplified cancers, and the company employs a biomarker-driven, tumor-agnostic development strategy ⁹. All ecDTx have been discovered internally, and the company retains global rights for all its programs ¹⁰.

Boundless Bio's lead ecDTx, BBI-940, is a novel, oral, selective degrader targeting a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation during mitosis ¹¹. BBI-940 has demonstrated potent anti-tumor activity in preclinical models, including single-agent tumor regressions ¹². In February 2026, the company initiated the Phase 1 KOMODO-1 clinical trial for BBI-940 in patients with ER+/HER2- breast cancer who have progressed following CDK4/6 inhibitor plus endocrine therapy, and in patients with TNBC-LAR ¹³. The trial will assess two distinct biomarkers for patient selection and retrospectively evaluate ecDNA status ¹⁴.

Previously, the company was investigating BBI-355, a CHK1 inhibitor, and BBI-825, an RNR inhibitor, in the POTENTIATE and STARMAP clinical trials, respectively ¹⁵. However, in May 2025, the monotherapy and combination arms of BBI-355 in the POTENTIATE trial were discontinued based on initial trial data ¹⁶. In January 2026, following a strategic portfolio review, enrollment in the remaining arm of the POTENTIATE trial (BBI-355 in combination with BBI-825) was ceased due to market considerations, clinical data, and prioritization of the BBI-940 program ¹⁷. The STARMAP trial for BBI-825 was wound down in 2025 ¹⁸.

For the fiscal year ended December 31, 2025, the company reported a net loss of $58.197 million ¹⁹, an improvement from a net loss of $65.363 million in the prior year ²⁰. Total operating expenses for 2025 were $63.552 million ²¹, down from $73.267 million in 2024 ²². Research and development (R&D) expenses decreased by $10.422 million to $44.845 million in 2025 from $55.267 million in 2024 ²³. General and administrative (G&A) expenses increased slightly by $0.707 million to $18.707 million in 2025 from $18.000 million in 2024 ²⁴. Other income, net, primarily interest income, decreased to $5.355 million in 2025 from $7.904 million in 2024 ²⁵. As of December 31, 2025, the company had cash, cash equivalents, and short-term investments of $117.6 million ²⁶ and an accumulated deficit of $259.7 million ²⁷.

The year-over-year decrease in R&D expenses was primarily driven by a $6.613 million reduction in direct program costs, mainly from reduced spending on the STARMAP and POTENTIATE trials, partially offset by increased investment in other development programs, primarily BBI-940 ²⁸. Personnel-related costs within R&D decreased by $4.080 million due to workforce reductions ²⁹. Outside services and consulting costs decreased by $2.409 million ³⁰, and lab and pharmacology supplies decreased by $1.319 million ³¹. These reductions were partially offset by a $3.979 million increase in facilities-related expenses due to the full-year impact of the corporate headquarters lease in 2025 ³². The increase in G&A expenses was mainly due to a $1.9 million increase in facilities-related costs from the corporate headquarters relocation, partially offset by a $1.2 million decrease in personnel-related costs due to workforce reductions ³³.

Significant operational developments during the period include the discontinuation of the BBI-355 monotherapy and combination arms in the POTENTIATE trial in May 2025 ³⁴, and the cessation of enrollment for the entire POTENTIATE trial in January 2026 to prioritize the BBI-940 program ³⁵. The STARMAP trial for BBI-825 was wound down in 2025 ³⁶. In February 2026, the company initiated the Phase 1 KOMODO-1 clinical trial for BBI-940 ³⁷. In April 2024, the company completed its IPO, selling 6,250,000 shares of common stock for gross proceeds of $100.0 million and net proceeds of approximately $87.7 million ³⁸. In April 2025, an "at the market" (ATM) offering was commenced, allowing the sale of common stock with an aggregate offering price of up to $14.5 million ³⁹.

Boundless Bio expects to have initial proof-of-concept safety and efficacy clinical data from the KOMODO-1 trial of BBI-940 within its existing cash runway timeline ⁴⁰. The company believes its existing cash, cash equivalents, and short-term investments of $117.6 million ⁴¹ as of December 31, 2025, will be sufficient to fund its operations into the second half of 2028 ⁴².

The primary growth area for Boundless Bio is the advancement of its lead ecDTx, BBI-940, through clinical development and regulatory approval in patients with metastatic breast cancer ⁴³. The KOMODO-1 trial, initiated in February 2026, is a Phase 1, open-label, multicenter, first-in-human clinical trial evaluating BBI-940 in patients with ER+/HER2- breast cancer who have progressed following CDK4/6 inhibitor plus endocrine therapy, and in patients with TNBC-LAR ⁴⁴. The trial is designed to evaluate safety, tolerability, human pharmacokinetics (PK), pharmacodynamic (PD) biomarkers, and preliminary antitumor activity, and to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BBI-940 as a single agent or in combination with fulvestrant ⁴⁵. The company anticipates enrolling approximately 60 to 96 patients in total across all parts of the trial ⁴⁶. If clinically meaningful antitumor activity with an acceptable safety and tolerability profile is demonstrated, the company intends to engage with the FDA and other global regulatory authorities to discuss future clinical development and registrational paths ⁴⁷.

Another growth vector involves leveraging the proprietary Spyglass platform to potentially identify additional development opportunities for BBI-940 and expand the therapeutic pipeline ⁴⁸. The Spyglass platform is continuously updated with new models, tools, and technologies to identify novel points of synthetic lethality in oncogene amplified cancers ⁴⁹. The company has preclinically validated multiple additional targets and has historically initiated ecDTx drug discovery efforts against certain targets ⁵⁰. Spyglass will continue to inform BBI-940 development and potential complementary targets or assets for future acquisition or internal development ⁵¹.

Operationally, the company expects its research and development (R&D) expenses to increase substantially in the long-term to support advanced clinical development of its ecDTx, hiring additional personnel, and maintaining, expanding, protecting, and enforcing its intellectual property portfolio ⁵². However, in the short term, the company intends to manage R&D expenses to enable delivery of initial proof-of-concept clinical data for BBI-940 ⁵³. General and administrative (G&A) expenses are also expected to increase substantially as the business grows and, if marketing approval is received, when commercialization activities commence ⁵⁴. The company anticipates increased facilities-related costs related to its current headquarters facilities and expects to incur ongoing expenses related to audit, legal, regulatory, and tax services associated with public company operations ⁵⁵.

The company does not own or operate manufacturing facilities and plans to continue relying on third parties for the manufacture of its ecDTx for preclinical and clinical testing, and for commercial manufacture if marketing approval is obtained ⁵⁶. This strategy aims to maintain an efficient infrastructure by avoiding investment in proprietary manufacturing facilities, equipment, and personnel, allowing focus on discovery and development ⁵⁷. The company is working with current manufacturers to scale up manufacturing capabilities to support clinical plans and plans to evaluate additional manufacturers to build supply chain redundancies ⁵⁸.

Planned capital allocation includes financing cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements ⁵⁹. The company may also use a portion of net proceeds from its IPO and existing cash, cash equivalents, and short-term investments to in-license, acquire, or invest in complementary businesses, technologies, products, or assets ⁶⁰.

Management has explicitly flagged several structural headwinds and execution risks. The company has a limited operating history, has incurred significant operating losses since inception, and expects to incur significant losses for the foreseeable future, with no guarantee of generating revenue or achieving sustained profitability ⁶¹. Substantial additional capital will be required to finance operations, and failure to obtain it could force delays, reductions, or termination of ecDTx development programs or commercialization efforts ⁶². The approach to treating cancer with ecDTx directed against ecDNA is novel and unproven, and there is no certainty of developing products of commercial value or that competing approaches will not limit commercial value ⁶³. Clinical and preclinical development is lengthy, expensive, and uncertain, with results not necessarily predictive of future outcomes ⁶⁴. Difficulties or delays in clinical trials, including patient enrollment, could increase costs or limit revenue generation ⁶⁵. Use of ecDTx could be associated with side effects or adverse events, potentially delaying or precluding regulatory approval or limiting commercial profiles ⁶⁶. The company relies on third parties for clinical trials, manufacturing, packaging, labeling, shipping, storage, and distribution, and unsatisfactory performance or cost could impair development or commercialization ⁶⁷. Disruptions at government agencies like the FDA and SEC, due to shutdowns, funding shortages, or policy changes, could impede development and marketing approval ⁶⁸.

Geographic, regulatory, and macro factors identified as constraints include the potential for the FDA and other foreign equivalents not to accept data from clinical trials conducted outside the United States, which could delay development plans ⁶⁹. The company is subject to various U.S. federal, state, and foreign healthcare laws and regulations, which could increase compliance costs and lead to significant fines or liability if violated ⁷⁰. Current and future healthcare reform legislation or regulation, such as the Inflation Reduction Act of 2022 (IRA) and the "One Big Beautiful Bill Act" (OBBBA), may increase the difficulty and cost of obtaining coverage and commercializing ecDTx and adversely affect pricing ⁷¹. Unstable market and economic conditions, including market volatility, high interest rates, inflation, tariffs, trade barriers, slowed economic growth, and geopolitical events, may have serious adverse consequences on the business, financial condition, and stock price ⁷².

Boundless Bio faces material macroeconomic, competitive, regulatory, geopolitical, and operational risks. The company has a limited operating history, has incurred significant operating losses of $58.197 million ⁷³ for the year ended December 31, 2025, and expects continued losses, requiring substantial additional capital that may not be available on acceptable terms ⁷⁴. The novel and unproven approach of developing ecDTx directed against ecDNA carries inherent uncertainty regarding commercial value and potential competition from companies developing novel treatments and technology platforms ⁷⁵. Clinical and preclinical development is lengthy, expensive, and uncertain, with a high failure rate, as evidenced by the discontinuation of the POTENTIATE trial for BBI-355 and BBI-825 ⁷⁶. Difficulties in patient enrollment, potential side effects or adverse events, and reliance on third parties for clinical trials and manufacturing pose significant operational risks that could delay or terminate development programs ⁷⁷. Regulatory risks include potential delays or denials of approval due to FDA or foreign regulatory authority disagreements on trial design, non-compliance with Good Clinical Practice (GCP) or Good Manufacturing Practice (cGMP) requirements, or the need for companion diagnostics ⁷⁸. Changes in healthcare reform legislation, such as the Inflation Reduction Act of 2022 and the "One Big Beautiful Bill Act," could increase the difficulty and cost of obtaining coverage and reimbursement for approved ecDTx, potentially limiting market acceptance and revenue generation ⁷⁹. Geopolitical events, including military conflicts, trade policies, tariffs, and sanctions, could disrupt supply chains, increase operating costs, and impact the ability to raise capital or operate in foreign markets ⁸⁰. Cybersecurity incidents affecting the company's or its service providers' information technology systems could compromise sensitive information, disrupt development programs, and lead to significant liability or fines ⁸¹. The company's long-term non-cancellable lease obligations, totaling $69.8 million ⁸² as of December 31, 2025, also represent a significant financial commitment that may limit operating flexibility and adversely affect liquidity ⁸³.

Management's message to shareholders conveys a focused and strategic shift towards prioritizing the lead ecDTx, BBI-940, following a comprehensive portfolio review. The company explicitly states its belief that existing cash, cash equivalents, and short-term investments will be sufficient to fund operations into the second half of 2028 ⁸⁴. This forward-looking statement is grounded in current operating plans and assumptions. The three strategic priorities emphasized for the period ahead are to advance BBI-940 through clinical development and regulatory approval in patients with metastatic breast cancer, to leverage the proprietary Spyglass platform to potentially identify additional development opportunities for BBI-940 and expand the therapeutic pipeline, and to opportunistically pursue strategic collaborations to accelerate development timelines and maximize the commercial potential of ecDTx.